Abrdn Life Sciences Investors (HQL)
NYSE: HQL · Real-Time Price · USD
16.95
+0.09 (0.53%)
Jun 12, 2026, 4:00 PM EDT - Market closed

HQL Income Statement

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Other Revenue
1.111.943.983.53.022.29
Revenue
1.111.943.983.53.022.29
Revenue Growth (YoY)
-66.13%-51.30%13.75%15.89%32.05%-32.59%
Gross Profit
1.111.943.983.53.022.29
Selling, General & Admin
5.865.315.95.676.016.43
Operating Expenses
5.865.315.95.676.016.43
Operating Income
-4.75-3.37-1.92-2.18-2.99-4.14
Currency Exchange Gain (Loss)
-0---00-0.01
Other Non Operating Income (Expenses)
1.610.850.69-1.752.08
EBT Excluding Unusual Items
-3.14-2.52-1.23-2.18-1.24-2.06
Gain (Loss) on Sale of Investments
201.3188.1186.5324.53-103.3766.59
Pretax Income
198.1785.5985.322.35-104.664.53
Net Income
198.1785.5985.322.35-104.664.53
Net Income to Common
198.1785.5985.322.35-104.664.53
Net Income Growth
-0.35%281.60%---47.56%
Shares Outstanding (Basic)
303028272625
Shares Outstanding (Diluted)
303028272625
Shares Change (YoY)
5.32%5.48%4.74%4.33%4.10%3.29%
EPS (Basic)
6.522.893.040.83-4.072.62
EPS (Diluted)
6.522.893.040.83-4.072.62
EPS Growth
--4.86%264.33%---49.23%
Dividend Per Share
0.8501.8201.6601.2801.4701.670
Dividend Growth
-56.19%9.64%29.69%-12.93%-11.98%13.61%
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-428.36%-174.11%-48.25%-62.18%-99.05%-181.04%
Profit Margin
17856.98%4415.74%2143.13%638.86%-3464.88%2822.50%
EBIT
-4.75-3.37-1.92-2.18-2.99-4.14
EBIT Margin
--174.11%-48.25%-62.18%-99.05%-181.04%
Revenue as Reported
1.111.943.983.53.022.29
SEC Filings: 10-K · 10-Q